nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—SLCO1B3—Rosuvastatin—atherosclerosis	0.0873	0.116	CbGbCtD
Dabrafenib—SLCO1B3—Pravastatin—atherosclerosis	0.0794	0.105	CbGbCtD
Dabrafenib—SLCO1B1—Ezetimibe—atherosclerosis	0.0508	0.0675	CbGbCtD
Dabrafenib—SLCO1B1—Rosuvastatin—atherosclerosis	0.0508	0.0675	CbGbCtD
Dabrafenib—SLCO1B1—Simvastatin—atherosclerosis	0.0473	0.0627	CbGbCtD
Dabrafenib—SLCO1B1—Lovastatin—atherosclerosis	0.0463	0.0614	CbGbCtD
Dabrafenib—SLCO1B1—Pravastatin—atherosclerosis	0.0463	0.0614	CbGbCtD
Dabrafenib—SLC22A8—Pravastatin—atherosclerosis	0.0427	0.0567	CbGbCtD
Dabrafenib—ABCG2—Rosuvastatin—atherosclerosis	0.0404	0.0536	CbGbCtD
Dabrafenib—ABCG2—Ezetimibe—atherosclerosis	0.0404	0.0536	CbGbCtD
Dabrafenib—ABCG2—Pravastatin—atherosclerosis	0.0367	0.0488	CbGbCtD
Dabrafenib—SLC22A6—Pravastatin—atherosclerosis	0.0297	0.0395	CbGbCtD
Dabrafenib—Panniculitis—Ezetimibe—atherosclerosis	0.0225	0.173	CcSEcCtD
Dabrafenib—CYP2C8—Simvastatin—atherosclerosis	0.02	0.0266	CbGbCtD
Dabrafenib—CYP2C8—Pravastatin—atherosclerosis	0.0196	0.026	CbGbCtD
Dabrafenib—CYP2C8—Lovastatin—atherosclerosis	0.0196	0.026	CbGbCtD
Dabrafenib—ABCB1—Ezetimibe—atherosclerosis	0.0146	0.0193	CbGbCtD
Dabrafenib—ABCB1—Simvastatin—atherosclerosis	0.0135	0.018	CbGbCtD
Dabrafenib—ABCB1—Pravastatin—atherosclerosis	0.0133	0.0176	CbGbCtD
Dabrafenib—ABCB1—Lovastatin—atherosclerosis	0.0133	0.0176	CbGbCtD
Dabrafenib—CYP3A4—Ezetimibe—atherosclerosis	0.00873	0.0116	CbGbCtD
Dabrafenib—CYP3A4—Rosuvastatin—atherosclerosis	0.00873	0.0116	CbGbCtD
Dabrafenib—CYP3A4—Simvastatin—atherosclerosis	0.00811	0.0108	CbGbCtD
Dabrafenib—CYP3A4—Pravastatin—atherosclerosis	0.00794	0.0105	CbGbCtD
Dabrafenib—CYP3A4—Lovastatin—atherosclerosis	0.00794	0.0105	CbGbCtD
Dabrafenib—Hyperkeratosis—Niacin—atherosclerosis	0.0033	0.0254	CcSEcCtD
Dabrafenib—Nephropathy—Rosuvastatin—atherosclerosis	0.00272	0.021	CcSEcCtD
Dabrafenib—Gamma-glutamyltransferase increased—Ezetimibe—atherosclerosis	0.00131	0.0101	CcSEcCtD
Dabrafenib—Neoplasm malignant—Ezetimibe—atherosclerosis	0.00126	0.00972	CcSEcCtD
Dabrafenib—Bone disorder—Ezetimibe—atherosclerosis	0.00119	0.00919	CcSEcCtD
Dabrafenib—Rash pustular—Niacin—atherosclerosis	0.00118	0.00911	CcSEcCtD
Dabrafenib—Gamma-glutamyltransferase increased—Pravastatin—atherosclerosis	0.00113	0.0087	CcSEcCtD
Dabrafenib—Phosphatase alkaline increased—Lovastatin—atherosclerosis	0.0011	0.00846	CcSEcCtD
Dabrafenib—Phosphatase alkaline increased—Ezetimibe—atherosclerosis	0.00108	0.0083	CcSEcCtD
Dabrafenib—Bone disorder—Niacin—atherosclerosis	0.00105	0.00805	CcSEcCtD
Dabrafenib—Hyperbilirubinaemia—Niacin—atherosclerosis	0.00104	0.00799	CcSEcCtD
Dabrafenib—Phosphatase alkaline increased—Simvastatin—atherosclerosis	0.00103	0.00792	CcSEcCtD
Dabrafenib—Renal failure acute—Rosuvastatin—atherosclerosis	0.00102	0.00785	CcSEcCtD
Dabrafenib—Phosphatase alkaline increased—Pravastatin—atherosclerosis	0.00093	0.00716	CcSEcCtD
Dabrafenib—Blood alkaline phosphatase increased—Lovastatin—atherosclerosis	0.000917	0.00706	CcSEcCtD
Dabrafenib—Blood alkaline phosphatase increased—Ezetimibe—atherosclerosis	0.0009	0.00693	CcSEcCtD
Dabrafenib—Rash maculo-papular—Niacin—atherosclerosis	0.000858	0.00661	CcSEcCtD
Dabrafenib—Blood alkaline phosphatase increased—Simvastatin—atherosclerosis	0.000858	0.00661	CcSEcCtD
Dabrafenib—Pain in extremity—Lovastatin—atherosclerosis	0.000798	0.00614	CcSEcCtD
Dabrafenib—Pancreatitis—Rosuvastatin—atherosclerosis	0.000798	0.00614	CcSEcCtD
Dabrafenib—Pain in extremity—Ezetimibe—atherosclerosis	0.000783	0.00603	CcSEcCtD
Dabrafenib—Blood alkaline phosphatase increased—Pravastatin—atherosclerosis	0.000776	0.00597	CcSEcCtD
Dabrafenib—Renal failure acute—Pravastatin—atherosclerosis	0.000731	0.00563	CcSEcCtD
Dabrafenib—Dermatitis bullous—Niacin—atherosclerosis	0.000717	0.00552	CcSEcCtD
Dabrafenib—Urinary tract infection—Rosuvastatin—atherosclerosis	0.000705	0.00543	CcSEcCtD
Dabrafenib—Aspartate aminotransferase increased—Ezetimibe—atherosclerosis	0.000705	0.00543	CcSEcCtD
Dabrafenib—Nasopharyngitis—Ezetimibe—atherosclerosis	0.0007	0.00539	CcSEcCtD
Dabrafenib—Haematuria—Rosuvastatin—atherosclerosis	0.000692	0.00533	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Ezetimibe—atherosclerosis	0.00069	0.00531	CcSEcCtD
Dabrafenib—Pancreatitis—Lovastatin—atherosclerosis	0.000676	0.00521	CcSEcCtD
Dabrafenib—Pancreatitis—Ezetimibe—atherosclerosis	0.000663	0.00511	CcSEcCtD
Dabrafenib—Abdominal discomfort—Lovastatin—atherosclerosis	0.000661	0.00509	CcSEcCtD
Dabrafenib—Pancreatitis—Simvastatin—atherosclerosis	0.000632	0.00487	CcSEcCtD
Dabrafenib—Dry skin—Niacin—atherosclerosis	0.000628	0.00484	CcSEcCtD
Dabrafenib—Dry skin—Pravastatin—atherosclerosis	0.000619	0.00476	CcSEcCtD
Dabrafenib—Abdominal discomfort—Simvastatin—atherosclerosis	0.000618	0.00476	CcSEcCtD
Dabrafenib—Nasopharyngitis—Pravastatin—atherosclerosis	0.000603	0.00465	CcSEcCtD
Dabrafenib—Infestation—Ezetimibe—atherosclerosis	0.000603	0.00464	CcSEcCtD
Dabrafenib—Infestation NOS—Ezetimibe—atherosclerosis	0.000603	0.00464	CcSEcCtD
Dabrafenib—Urinary tract infection—Lovastatin—atherosclerosis	0.000598	0.0046	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Pravastatin—atherosclerosis	0.000595	0.00458	CcSEcCtD
Dabrafenib—Arrhythmia—Rosuvastatin—atherosclerosis	0.000582	0.00448	CcSEcCtD
Dabrafenib—Pancreatitis—Pravastatin—atherosclerosis	0.000572	0.0044	CcSEcCtD
Dabrafenib—Mental disorder—Rosuvastatin—atherosclerosis	0.000571	0.00439	CcSEcCtD
Dabrafenib—Oedema peripheral—Ezetimibe—atherosclerosis	0.000533	0.00411	CcSEcCtD
Dabrafenib—Connective tissue disorder—Ezetimibe—atherosclerosis	0.000532	0.0041	CcSEcCtD
Dabrafenib—Stomatitis—Niacin—atherosclerosis	0.000515	0.00396	CcSEcCtD
Dabrafenib—Urinary tract infection—Pravastatin—atherosclerosis	0.000505	0.00389	CcSEcCtD
Dabrafenib—Chills—Lovastatin—atherosclerosis	0.000495	0.00381	CcSEcCtD
Dabrafenib—Cough—Rosuvastatin—atherosclerosis	0.000495	0.00381	CcSEcCtD
Dabrafenib—Angiopathy—Ezetimibe—atherosclerosis	0.000491	0.00378	CcSEcCtD
Dabrafenib—Immune system disorder—Ezetimibe—atherosclerosis	0.000489	0.00377	CcSEcCtD
Dabrafenib—Mediastinal disorder—Ezetimibe—atherosclerosis	0.000488	0.00376	CcSEcCtD
Dabrafenib—Alopecia—Lovastatin—atherosclerosis	0.000488	0.00376	CcSEcCtD
Dabrafenib—Myalgia—Rosuvastatin—atherosclerosis	0.000483	0.00372	CcSEcCtD
Dabrafenib—Arthralgia—Rosuvastatin—atherosclerosis	0.000483	0.00372	CcSEcCtD
Dabrafenib—Alopecia—Ezetimibe—atherosclerosis	0.000478	0.00368	CcSEcCtD
Dabrafenib—Haemoglobin—Niacin—atherosclerosis	0.000477	0.00367	CcSEcCtD
Dabrafenib—Mental disorder—Ezetimibe—atherosclerosis	0.000474	0.00365	CcSEcCtD
Dabrafenib—Haemorrhage—Niacin—atherosclerosis	0.000474	0.00365	CcSEcCtD
Dabrafenib—Malnutrition—Ezetimibe—atherosclerosis	0.000471	0.00363	CcSEcCtD
Dabrafenib—Erythema—Ezetimibe—atherosclerosis	0.000471	0.00363	CcSEcCtD
Dabrafenib—Oedema peripheral—Niacin—atherosclerosis	0.000467	0.0036	CcSEcCtD
Dabrafenib—Back pain—Lovastatin—atherosclerosis	0.000465	0.00358	CcSEcCtD
Dabrafenib—Chills—Simvastatin—atherosclerosis	0.000463	0.00357	CcSEcCtD
Dabrafenib—Muscle spasms—Lovastatin—atherosclerosis	0.000462	0.00356	CcSEcCtD
Dabrafenib—Infection—Rosuvastatin—atherosclerosis	0.00046	0.00354	CcSEcCtD
Dabrafenib—Alopecia—Simvastatin—atherosclerosis	0.000456	0.00351	CcSEcCtD
Dabrafenib—Back pain—Ezetimibe—atherosclerosis	0.000456	0.00351	CcSEcCtD
Dabrafenib—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000454	0.00349	CcSEcCtD
Dabrafenib—Muscle spasms—Ezetimibe—atherosclerosis	0.000453	0.00349	CcSEcCtD
Dabrafenib—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.000453	0.00349	CcSEcCtD
Dabrafenib—Vision blurred—Lovastatin—atherosclerosis	0.000453	0.00349	CcSEcCtD
Dabrafenib—Mental disorder—Simvastatin—atherosclerosis	0.000452	0.00348	CcSEcCtD
Dabrafenib—Erythema—Simvastatin—atherosclerosis	0.000449	0.00346	CcSEcCtD
Dabrafenib—Eye disorder—Niacin—atherosclerosis	0.000443	0.00341	CcSEcCtD
Dabrafenib—Anaemia—Ezetimibe—atherosclerosis	0.000436	0.00335	CcSEcCtD
Dabrafenib—Muscle spasms—Simvastatin—atherosclerosis	0.000432	0.00333	CcSEcCtD
Dabrafenib—Angiopathy—Niacin—atherosclerosis	0.00043	0.00331	CcSEcCtD
Dabrafenib—Leukopenia—Lovastatin—atherosclerosis	0.00043	0.00331	CcSEcCtD
Dabrafenib—Chills—Niacin—atherosclerosis	0.000425	0.00328	CcSEcCtD
Dabrafenib—Vision blurred—Simvastatin—atherosclerosis	0.000424	0.00326	CcSEcCtD
Dabrafenib—Arrhythmia—Niacin—atherosclerosis	0.000424	0.00326	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000422	0.00325	CcSEcCtD
Dabrafenib—Alopecia—Niacin—atherosclerosis	0.000419	0.00323	CcSEcCtD
Dabrafenib—Chills—Pravastatin—atherosclerosis	0.000419	0.00322	CcSEcCtD
Dabrafenib—Insomnia—Rosuvastatin—atherosclerosis	0.000419	0.00322	CcSEcCtD
Dabrafenib—Arrhythmia—Pravastatin—atherosclerosis	0.000417	0.00321	CcSEcCtD
Dabrafenib—Anaemia—Simvastatin—atherosclerosis	0.000415	0.0032	CcSEcCtD
Dabrafenib—Erythema—Niacin—atherosclerosis	0.000413	0.00318	CcSEcCtD
Dabrafenib—Malnutrition—Niacin—atherosclerosis	0.000413	0.00318	CcSEcCtD
Dabrafenib—Alopecia—Pravastatin—atherosclerosis	0.000413	0.00318	CcSEcCtD
Dabrafenib—Cough—Ezetimibe—atherosclerosis	0.000411	0.00317	CcSEcCtD
Dabrafenib—Arthralgia—Lovastatin—atherosclerosis	0.000409	0.00315	CcSEcCtD
Dabrafenib—Myalgia—Lovastatin—atherosclerosis	0.000409	0.00315	CcSEcCtD
Dabrafenib—Hypertension—Ezetimibe—atherosclerosis	0.000407	0.00313	CcSEcCtD
Dabrafenib—Leukopenia—Simvastatin—atherosclerosis	0.000402	0.0031	CcSEcCtD
Dabrafenib—Arthralgia—Ezetimibe—atherosclerosis	0.000401	0.00309	CcSEcCtD
Dabrafenib—Myalgia—Ezetimibe—atherosclerosis	0.000401	0.00309	CcSEcCtD
Dabrafenib—Dry mouth—Lovastatin—atherosclerosis	0.0004	0.00308	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000399	0.00307	CcSEcCtD
Dabrafenib—Muscle spasms—Niacin—atherosclerosis	0.000397	0.00306	CcSEcCtD
Dabrafenib—Constipation—Rosuvastatin—atherosclerosis	0.000396	0.00305	CcSEcCtD
Dabrafenib—Dry mouth—Ezetimibe—atherosclerosis	0.000392	0.00302	CcSEcCtD
Dabrafenib—Muscle spasms—Pravastatin—atherosclerosis	0.000391	0.00301	CcSEcCtD
Dabrafenib—Infection—Lovastatin—atherosclerosis	0.00039	0.003	CcSEcCtD
Dabrafenib—Vision blurred—Niacin—atherosclerosis	0.000389	0.00299	CcSEcCtD
Dabrafenib—Thrombocytopenia—Lovastatin—atherosclerosis	0.000384	0.00296	CcSEcCtD
Dabrafenib—Vision blurred—Pravastatin—atherosclerosis	0.000383	0.00295	CcSEcCtD
Dabrafenib—Myalgia—Simvastatin—atherosclerosis	0.000383	0.00295	CcSEcCtD
Dabrafenib—Arthralgia—Simvastatin—atherosclerosis	0.000383	0.00295	CcSEcCtD
Dabrafenib—Infection—Ezetimibe—atherosclerosis	0.000382	0.00294	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000378	0.00291	CcSEcCtD
Dabrafenib—Nervous system disorder—Ezetimibe—atherosclerosis	0.000377	0.0029	CcSEcCtD
Dabrafenib—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000377	0.0029	CcSEcCtD
Dabrafenib—Anaemia—Pravastatin—atherosclerosis	0.000376	0.00289	CcSEcCtD
Dabrafenib—Skin disorder—Ezetimibe—atherosclerosis	0.000374	0.00288	CcSEcCtD
Dabrafenib—Leukopenia—Niacin—atherosclerosis	0.000369	0.00284	CcSEcCtD
Dabrafenib—Oedema—Simvastatin—atherosclerosis	0.000367	0.00282	CcSEcCtD
Dabrafenib—Abdominal pain—Rosuvastatin—atherosclerosis	0.000366	0.00282	CcSEcCtD
Dabrafenib—Infection—Simvastatin—atherosclerosis	0.000364	0.00281	CcSEcCtD
Dabrafenib—Leukopenia—Pravastatin—atherosclerosis	0.000364	0.0028	CcSEcCtD
Dabrafenib—Cough—Niacin—atherosclerosis	0.00036	0.00277	CcSEcCtD
Dabrafenib—Thrombocytopenia—Simvastatin—atherosclerosis	0.000359	0.00277	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000357	0.00275	CcSEcCtD
Dabrafenib—Insomnia—Lovastatin—atherosclerosis	0.000355	0.00273	CcSEcCtD
Dabrafenib—Cough—Pravastatin—atherosclerosis	0.000355	0.00273	CcSEcCtD
Dabrafenib—Myalgia—Niacin—atherosclerosis	0.000351	0.00271	CcSEcCtD
Dabrafenib—Arthralgia—Niacin—atherosclerosis	0.000351	0.00271	CcSEcCtD
Dabrafenib—Hypertension—Pravastatin—atherosclerosis	0.000351	0.0027	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.00035	0.0027	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000349	0.00269	CcSEcCtD
Dabrafenib—Insomnia—Ezetimibe—atherosclerosis	0.000348	0.00268	CcSEcCtD
Dabrafenib—Myalgia—Pravastatin—atherosclerosis	0.000346	0.00266	CcSEcCtD
Dabrafenib—Arthralgia—Pravastatin—atherosclerosis	0.000346	0.00266	CcSEcCtD
Dabrafenib—Dry mouth—Niacin—atherosclerosis	0.000344	0.00265	CcSEcCtD
Dabrafenib—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000341	0.00263	CcSEcCtD
Dabrafenib—Decreased appetite—Lovastatin—atherosclerosis	0.000341	0.00262	CcSEcCtD
Dabrafenib—Fatigue—Lovastatin—atherosclerosis	0.000338	0.0026	CcSEcCtD
Dabrafenib—Oedema—Niacin—atherosclerosis	0.000337	0.00259	CcSEcCtD
Dabrafenib—Constipation—Lovastatin—atherosclerosis	0.000335	0.00258	CcSEcCtD
Dabrafenib—Decreased appetite—Ezetimibe—atherosclerosis	0.000334	0.00257	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000334	0.00257	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000332	0.00256	CcSEcCtD
Dabrafenib—Asthenia—Rosuvastatin—atherosclerosis	0.000332	0.00256	CcSEcCtD
Dabrafenib—Insomnia—Simvastatin—atherosclerosis	0.000332	0.00255	CcSEcCtD
Dabrafenib—Oedema—Pravastatin—atherosclerosis	0.000332	0.00255	CcSEcCtD
Dabrafenib—Fatigue—Ezetimibe—atherosclerosis	0.000332	0.00255	CcSEcCtD
Dabrafenib—Infection—Pravastatin—atherosclerosis	0.000329	0.00254	CcSEcCtD
Dabrafenib—Constipation—Ezetimibe—atherosclerosis	0.000329	0.00253	CcSEcCtD
Dabrafenib—Pruritus—Rosuvastatin—atherosclerosis	0.000327	0.00252	CcSEcCtD
Dabrafenib—Skin disorder—Niacin—atherosclerosis	0.000327	0.00252	CcSEcCtD
Dabrafenib—Hyperhidrosis—Niacin—atherosclerosis	0.000326	0.00251	CcSEcCtD
Dabrafenib—Thrombocytopenia—Pravastatin—atherosclerosis	0.000325	0.0025	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000321	0.00247	CcSEcCtD
Dabrafenib—Hyperhidrosis—Pravastatin—atherosclerosis	0.000321	0.00247	CcSEcCtD
Dabrafenib—Decreased appetite—Simvastatin—atherosclerosis	0.000319	0.00246	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000317	0.00244	CcSEcCtD
Dabrafenib—Diarrhoea—Rosuvastatin—atherosclerosis	0.000317	0.00244	CcSEcCtD
Dabrafenib—Fatigue—Simvastatin—atherosclerosis	0.000316	0.00244	CcSEcCtD
Dabrafenib—Hypotension—Niacin—atherosclerosis	0.000315	0.00242	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000315	0.00242	CcSEcCtD
Dabrafenib—Constipation—Simvastatin—atherosclerosis	0.000314	0.00242	CcSEcCtD
Dabrafenib—Abdominal pain—Lovastatin—atherosclerosis	0.00031	0.00239	CcSEcCtD
Dabrafenib—Body temperature increased—Lovastatin—atherosclerosis	0.00031	0.00239	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000307	0.00236	CcSEcCtD
Dabrafenib—Dizziness—Rosuvastatin—atherosclerosis	0.000306	0.00236	CcSEcCtD
Dabrafenib—Insomnia—Niacin—atherosclerosis	0.000305	0.00235	CcSEcCtD
Dabrafenib—Abdominal pain—Ezetimibe—atherosclerosis	0.000304	0.00234	CcSEcCtD
Dabrafenib—Body temperature increased—Ezetimibe—atherosclerosis	0.000304	0.00234	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000302	0.00233	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Simvastatin—atherosclerosis	0.0003	0.00231	CcSEcCtD
Dabrafenib—Insomnia—Pravastatin—atherosclerosis	0.0003	0.00231	CcSEcCtD
Dabrafenib—Decreased appetite—Niacin—atherosclerosis	0.000293	0.00225	CcSEcCtD
Dabrafenib—Rash—Rosuvastatin—atherosclerosis	0.000292	0.00225	CcSEcCtD
Dabrafenib—Dermatitis—Rosuvastatin—atherosclerosis	0.000292	0.00224	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Niacin—atherosclerosis	0.000291	0.00224	CcSEcCtD
Dabrafenib—Abdominal pain—Simvastatin—atherosclerosis	0.00029	0.00223	CcSEcCtD
Dabrafenib—Body temperature increased—Simvastatin—atherosclerosis	0.00029	0.00223	CcSEcCtD
Dabrafenib—Headache—Rosuvastatin—atherosclerosis	0.00029	0.00223	CcSEcCtD
Dabrafenib—Hypersensitivity—Lovastatin—atherosclerosis	0.000289	0.00222	CcSEcCtD
Dabrafenib—Decreased appetite—Pravastatin—atherosclerosis	0.000288	0.00222	CcSEcCtD
Dabrafenib—Fatigue—Pravastatin—atherosclerosis	0.000286	0.0022	CcSEcCtD
Dabrafenib—Constipation—Pravastatin—atherosclerosis	0.000284	0.00218	CcSEcCtD
Dabrafenib—Hypersensitivity—Ezetimibe—atherosclerosis	0.000283	0.00218	CcSEcCtD
Dabrafenib—Asthenia—Lovastatin—atherosclerosis	0.000281	0.00217	CcSEcCtD
Dabrafenib—Pruritus—Lovastatin—atherosclerosis	0.000277	0.00214	CcSEcCtD
Dabrafenib—Asthenia—Ezetimibe—atherosclerosis	0.000276	0.00212	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Niacin—atherosclerosis	0.000275	0.00212	CcSEcCtD
Dabrafenib—Nausea—Rosuvastatin—atherosclerosis	0.000275	0.00212	CcSEcCtD
Dabrafenib—Pruritus—Ezetimibe—atherosclerosis	0.000272	0.0021	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000271	0.00209	CcSEcCtD
Dabrafenib—Hypersensitivity—Simvastatin—atherosclerosis	0.00027	0.00208	CcSEcCtD
Dabrafenib—Diarrhoea—Lovastatin—atherosclerosis	0.000268	0.00207	CcSEcCtD
Dabrafenib—Abdominal pain—Niacin—atherosclerosis	0.000266	0.00205	CcSEcCtD
Dabrafenib—Body temperature increased—Niacin—atherosclerosis	0.000266	0.00205	CcSEcCtD
Dabrafenib—Asthenia—Simvastatin—atherosclerosis	0.000263	0.00203	CcSEcCtD
Dabrafenib—Diarrhoea—Ezetimibe—atherosclerosis	0.000263	0.00203	CcSEcCtD
Dabrafenib—Body temperature increased—Pravastatin—atherosclerosis	0.000262	0.00202	CcSEcCtD
Dabrafenib—Abdominal pain—Pravastatin—atherosclerosis	0.000262	0.00202	CcSEcCtD
Dabrafenib—Pruritus—Simvastatin—atherosclerosis	0.00026	0.002	CcSEcCtD
Dabrafenib—Dizziness—Lovastatin—atherosclerosis	0.000259	0.002	CcSEcCtD
Dabrafenib—Dizziness—Ezetimibe—atherosclerosis	0.000254	0.00196	CcSEcCtD
Dabrafenib—Diarrhoea—Simvastatin—atherosclerosis	0.000251	0.00193	CcSEcCtD
Dabrafenib—Vomiting—Lovastatin—atherosclerosis	0.000249	0.00192	CcSEcCtD
Dabrafenib—Hypersensitivity—Niacin—atherosclerosis	0.000248	0.00191	CcSEcCtD
Dabrafenib—Rash—Lovastatin—atherosclerosis	0.000247	0.0019	CcSEcCtD
Dabrafenib—Dermatitis—Lovastatin—atherosclerosis	0.000247	0.0019	CcSEcCtD
Dabrafenib—Headache—Lovastatin—atherosclerosis	0.000246	0.00189	CcSEcCtD
Dabrafenib—Vomiting—Ezetimibe—atherosclerosis	0.000245	0.00188	CcSEcCtD
Dabrafenib—Hypersensitivity—Pravastatin—atherosclerosis	0.000244	0.00188	CcSEcCtD
Dabrafenib—Dizziness—Simvastatin—atherosclerosis	0.000243	0.00187	CcSEcCtD
Dabrafenib—Rash—Ezetimibe—atherosclerosis	0.000243	0.00187	CcSEcCtD
Dabrafenib—Dermatitis—Ezetimibe—atherosclerosis	0.000242	0.00187	CcSEcCtD
Dabrafenib—Asthenia—Niacin—atherosclerosis	0.000242	0.00186	CcSEcCtD
Dabrafenib—Headache—Ezetimibe—atherosclerosis	0.000241	0.00186	CcSEcCtD
Dabrafenib—Pruritus—Niacin—atherosclerosis	0.000238	0.00183	CcSEcCtD
Dabrafenib—Asthenia—Pravastatin—atherosclerosis	0.000238	0.00183	CcSEcCtD
Dabrafenib—Pruritus—Pravastatin—atherosclerosis	0.000235	0.00181	CcSEcCtD
Dabrafenib—Vomiting—Simvastatin—atherosclerosis	0.000233	0.0018	CcSEcCtD
Dabrafenib—Nausea—Lovastatin—atherosclerosis	0.000233	0.00179	CcSEcCtD
Dabrafenib—Rash—Simvastatin—atherosclerosis	0.000231	0.00178	CcSEcCtD
Dabrafenib—Dermatitis—Simvastatin—atherosclerosis	0.000231	0.00178	CcSEcCtD
Dabrafenib—Diarrhoea—Niacin—atherosclerosis	0.00023	0.00177	CcSEcCtD
Dabrafenib—Headache—Simvastatin—atherosclerosis	0.00023	0.00177	CcSEcCtD
Dabrafenib—Nausea—Ezetimibe—atherosclerosis	0.000228	0.00176	CcSEcCtD
Dabrafenib—Diarrhoea—Pravastatin—atherosclerosis	0.000227	0.00175	CcSEcCtD
Dabrafenib—Dizziness—Niacin—atherosclerosis	0.000223	0.00171	CcSEcCtD
Dabrafenib—Dizziness—Pravastatin—atherosclerosis	0.000219	0.00169	CcSEcCtD
Dabrafenib—Nausea—Simvastatin—atherosclerosis	0.000218	0.00168	CcSEcCtD
Dabrafenib—Vomiting—Niacin—atherosclerosis	0.000214	0.00165	CcSEcCtD
Dabrafenib—Rash—Niacin—atherosclerosis	0.000212	0.00164	CcSEcCtD
Dabrafenib—Dermatitis—Niacin—atherosclerosis	0.000212	0.00163	CcSEcCtD
Dabrafenib—Headache—Niacin—atherosclerosis	0.000211	0.00162	CcSEcCtD
Dabrafenib—Vomiting—Pravastatin—atherosclerosis	0.000211	0.00162	CcSEcCtD
Dabrafenib—Rash—Pravastatin—atherosclerosis	0.000209	0.00161	CcSEcCtD
Dabrafenib—Dermatitis—Pravastatin—atherosclerosis	0.000209	0.00161	CcSEcCtD
Dabrafenib—Headache—Pravastatin—atherosclerosis	0.000208	0.0016	CcSEcCtD
Dabrafenib—Nausea—Niacin—atherosclerosis	0.0002	0.00154	CcSEcCtD
Dabrafenib—Nausea—Pravastatin—atherosclerosis	0.000197	0.00152	CcSEcCtD
Dabrafenib—SLCO1B3—Metabolism—INS—atherosclerosis	1.07e-05	9.14e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CAV1—atherosclerosis	1.07e-05	9.13e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—APOA1—atherosclerosis	1.06e-05	9.11e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—APOE—atherosclerosis	1.06e-05	9.11e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—LTA4H—atherosclerosis	1.06e-05	9.1e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ABCG8—atherosclerosis	1.06e-05	9.1e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CCL2—atherosclerosis	1.06e-05	9.07e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ALOX5—atherosclerosis	1.06e-05	9.06e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CAV1—atherosclerosis	1.05e-05	9.02e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PTGS2—atherosclerosis	1.05e-05	9.02e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PLG—atherosclerosis	1.05e-05	9.01e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—APOA1—atherosclerosis	1.05e-05	9e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—APOB—atherosclerosis	1.05e-05	8.98e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—atherosclerosis	1.04e-05	8.95e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—TNF—atherosclerosis	1.04e-05	8.87e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—LPA—atherosclerosis	1.03e-05	8.85e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—ESR1—atherosclerosis	1.03e-05	8.8e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—GSTM1—atherosclerosis	1.02e-05	8.73e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—F2—atherosclerosis	1.01e-05	8.69e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—HMOX1—atherosclerosis	1.01e-05	8.68e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—MAPK3—atherosclerosis	1.01e-05	8.65e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—BGN—atherosclerosis	1e-05	8.57e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—LPL—atherosclerosis	1e-05	8.57e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SOCS3—atherosclerosis	9.96e-06	8.54e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NOS2—atherosclerosis	9.91e-06	8.49e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—APOA5—atherosclerosis	9.91e-06	8.49e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—ALB—atherosclerosis	9.78e-06	8.37e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	9.77e-06	8.37e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—GPX1—atherosclerosis	9.76e-06	8.36e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PIK3CG—atherosclerosis	9.71e-06	8.32e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—APOB—atherosclerosis	9.7e-06	8.31e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MMP3—atherosclerosis	9.62e-06	8.24e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IGF2—atherosclerosis	9.58e-06	8.21e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PLA2G1B—atherosclerosis	9.53e-06	8.17e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CD36—atherosclerosis	9.51e-06	8.14e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—NAMPT—atherosclerosis	9.48e-06	8.12e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—PPARA—atherosclerosis	9.45e-06	8.09e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—GSTM1—atherosclerosis	9.44e-06	8.09e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	9.43e-06	8.07e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—LIPC—atherosclerosis	9.42e-06	8.07e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—APOC3—atherosclerosis	9.36e-06	8.02e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—NOS3—atherosclerosis	9.35e-06	8.01e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—LDLR—atherosclerosis	9.31e-06	7.97e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—APOB—atherosclerosis	9.3e-06	7.97e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—LPL—atherosclerosis	9.26e-06	7.94e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ALOX5—atherosclerosis	9.21e-06	7.89e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—INS—atherosclerosis	9.19e-06	7.87e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—EDN1—atherosclerosis	9.15e-06	7.84e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CETP—atherosclerosis	9.09e-06	7.79e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCL5—atherosclerosis	9.08e-06	7.78e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—INS—atherosclerosis	9.08e-06	7.78e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCL2—atherosclerosis	9.04e-06	7.75e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—GPX1—atherosclerosis	9.04e-06	7.74e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—MTHFR—atherosclerosis	9.01e-06	7.72e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IGF1—atherosclerosis	8.89e-06	7.62e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—LPL—atherosclerosis	8.88e-06	7.61e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—APOA1—atherosclerosis	8.86e-06	7.59e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PPARA—atherosclerosis	8.84e-06	7.57e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CD36—atherosclerosis	8.8e-06	7.54e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—SCARB1—atherosclerosis	8.7e-06	7.46e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PRKCG—atherosclerosis	8.64e-06	7.4e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—AGT—atherosclerosis	8.56e-06	7.33e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PTGS2—atherosclerosis	8.55e-06	7.33e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	8.47e-06	7.26e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SERPINE1—atherosclerosis	8.44e-06	7.23e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SPP1—atherosclerosis	8.41e-06	7.21e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ABCG1—atherosclerosis	8.4e-06	7.2e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—APOE—atherosclerosis	8.39e-06	7.18e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CXCL8—atherosclerosis	8.37e-06	7.17e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—IL6—atherosclerosis	8.36e-06	7.16e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—SERPINE1—atherosclerosis	8.34e-06	7.15e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—MTHFR—atherosclerosis	8.34e-06	7.15e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CAV1—atherosclerosis	8.31e-06	7.12e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—APOA1—atherosclerosis	8.29e-06	7.1e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—NAMPT—atherosclerosis	8.26e-06	7.08e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IFNG—atherosclerosis	8.23e-06	7.05e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—HMGCR—atherosclerosis	8.22e-06	7.04e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—STAT3—atherosclerosis	8.21e-06	7.03e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—LIPC—atherosclerosis	8.21e-06	7.03e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PPARA—atherosclerosis	8.18e-06	7.01e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—APOC3—atherosclerosis	8.16e-06	6.99e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—LDLR—atherosclerosis	8.11e-06	6.95e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NOS3—atherosclerosis	8.06e-06	6.91e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NOS3—atherosclerosis	7.96e-06	6.82e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—AGT—atherosclerosis	7.93e-06	6.79e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CETP—atherosclerosis	7.92e-06	6.78e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—FABP4—atherosclerosis	7.9e-06	6.77e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—LCAT—atherosclerosis	7.9e-06	6.77e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MAPK3—atherosclerosis	7.85e-06	6.72e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PDGFB—atherosclerosis	7.78e-06	6.67e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—atherosclerosis	7.77e-06	6.66e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—APOE—atherosclerosis	7.77e-06	6.65e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—APOA4—atherosclerosis	7.75e-06	6.64e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—AKT1—atherosclerosis	7.71e-06	6.6e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CAV1—atherosclerosis	7.69e-06	6.59e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—APOA1—atherosclerosis	7.68e-06	6.58e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP7A1—atherosclerosis	7.61e-06	6.52e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—TGFB1—atherosclerosis	7.61e-06	6.52e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AGT—atherosclerosis	7.6e-06	6.51e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—SCARB1—atherosclerosis	7.58e-06	6.5e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CG—atherosclerosis	7.57e-06	6.48e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—AKT1—atherosclerosis	7.56e-06	6.48e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—APOE—atherosclerosis	7.44e-06	6.38e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—LEP—atherosclerosis	7.44e-06	6.38e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	7.41e-06	6.35e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—IL6—atherosclerosis	7.38e-06	6.32e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CAV1—atherosclerosis	7.38e-06	6.32e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—APOA1—atherosclerosis	7.36e-06	6.3e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL1B—atherosclerosis	7.34e-06	6.29e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ABCA1—atherosclerosis	7.33e-06	6.28e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PPARG—atherosclerosis	7.3e-06	6.26e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PTGS2—atherosclerosis	7.28e-06	6.24e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—INS—atherosclerosis	7.16e-06	6.14e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—HMGCR—atherosclerosis	7.16e-06	6.13e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CXCL8—atherosclerosis	7.15e-06	6.13e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ESR1—atherosclerosis	7.11e-06	6.09e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP27A1—atherosclerosis	7.04e-06	6.03e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—ALB—atherosclerosis	7.02e-06	6.01e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—F2—atherosclerosis	7.02e-06	6.01e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CG—atherosclerosis	7.01e-06	6e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—NFKB1—atherosclerosis	6.85e-06	5.87e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—AKT1—atherosclerosis	6.81e-06	5.83e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PPARG—atherosclerosis	6.76e-06	5.79e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—MAPK8—atherosclerosis	6.73e-06	5.77e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CG—atherosclerosis	6.72e-06	5.76e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—APOA2—atherosclerosis	6.67e-06	5.72e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	6.67e-06	5.72e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	6.67e-06	5.72e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ALOX15—atherosclerosis	6.67e-06	5.72e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—INS—atherosclerosis	6.63e-06	5.68e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ABCG5—atherosclerosis	6.59e-06	5.65e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ALB—atherosclerosis	6.57e-06	5.63e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—AKT1—atherosclerosis	6.54e-06	5.6e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MMP9—atherosclerosis	6.47e-06	5.54e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—MAPK3—atherosclerosis	6.43e-06	5.51e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NFKB1—atherosclerosis	6.4e-06	5.48e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ABCA1—atherosclerosis	6.38e-06	5.47e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—LPA—atherosclerosis	6.37e-06	5.45e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—INS—atherosclerosis	6.36e-06	5.45e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MAPK8—atherosclerosis	6.29e-06	5.39e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—HMOX1—atherosclerosis	6.29e-06	5.38e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—NOS3—atherosclerosis	6.28e-06	5.38e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCL2—atherosclerosis	6.26e-06	5.36e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—BGN—atherosclerosis	6.16e-06	5.28e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—STAT3—atherosclerosis	6.15e-06	5.27e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IGF1—atherosclerosis	6.15e-06	5.27e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—APOA5—atherosclerosis	6.1e-06	5.23e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ALB—atherosclerosis	6.08e-06	5.21e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—APOB—atherosclerosis	6.02e-06	5.16e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—MAPK3—atherosclerosis	5.88e-06	5.04e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	5.87e-06	5.03e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GSTM1—atherosclerosis	5.86e-06	5.02e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SERPINE1—atherosclerosis	5.84e-06	5e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—NOS3—atherosclerosis	5.82e-06	4.98e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—VEGFA—atherosclerosis	5.81e-06	4.98e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—STAT3—atherosclerosis	5.75e-06	4.93e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—LPL—atherosclerosis	5.75e-06	4.93e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PTGS2—atherosclerosis	5.75e-06	4.92e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—IL6—atherosclerosis	5.74e-06	4.91e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—STAT3—atherosclerosis	5.68e-06	4.87e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ALOX5—atherosclerosis	5.67e-06	4.86e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GPX1—atherosclerosis	5.61e-06	4.81e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NOS3—atherosclerosis	5.58e-06	4.78e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MAPK3—atherosclerosis	5.49e-06	4.71e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—HMOX1—atherosclerosis	5.48e-06	4.69e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CD36—atherosclerosis	5.46e-06	4.68e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MAPK3—atherosclerosis	5.43e-06	4.65e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TGFB1—atherosclerosis	5.33e-06	4.57e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PTGS2—atherosclerosis	5.32e-06	4.56e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—AKT1—atherosclerosis	5.29e-06	4.53e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—TGFB1—atherosclerosis	5.27e-06	4.51e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—APOB—atherosclerosis	5.25e-06	4.49e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—MTHFR—atherosclerosis	5.18e-06	4.43e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GSTM1—atherosclerosis	5.1e-06	4.37e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NAMPT—atherosclerosis	5.09e-06	4.36e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PPARA—atherosclerosis	5.08e-06	4.35e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—LIPC—atherosclerosis	5.06e-06	4.33e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—APOC3—atherosclerosis	5.03e-06	4.31e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—LPL—atherosclerosis	5.01e-06	4.29e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—LDLR—atherosclerosis	4.99e-06	4.28e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CXCL8—atherosclerosis	4.95e-06	4.24e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—AGT—atherosclerosis	4.92e-06	4.21e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GPX1—atherosclerosis	4.89e-06	4.19e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CETP—atherosclerosis	4.88e-06	4.18e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—APOE—atherosclerosis	4.82e-06	4.13e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CAV1—atherosclerosis	4.77e-06	4.09e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—APOA1—atherosclerosis	4.76e-06	4.08e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CD36—atherosclerosis	4.76e-06	4.08e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL6—atherosclerosis	4.7e-06	4.03e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SCARB1—atherosclerosis	4.67e-06	4e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—MTHFR—atherosclerosis	4.51e-06	3.86e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MMP9—atherosclerosis	4.47e-06	3.83e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NFKB1—atherosclerosis	4.43e-06	3.79e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PPARA—atherosclerosis	4.42e-06	3.79e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HMGCR—atherosclerosis	4.41e-06	3.78e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MAPK8—atherosclerosis	4.35e-06	3.73e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CG—atherosclerosis	4.35e-06	3.73e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—AKT1—atherosclerosis	4.34e-06	3.72e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—AKT1—atherosclerosis	4.3e-06	3.68e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL6—atherosclerosis	4.3e-06	3.68e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—AGT—atherosclerosis	4.28e-06	3.67e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—APOE—atherosclerosis	4.2e-06	3.6e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PPARG—atherosclerosis	4.2e-06	3.6e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CAV1—atherosclerosis	4.16e-06	3.56e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—APOA1—atherosclerosis	4.15e-06	3.56e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—INS—atherosclerosis	4.12e-06	3.53e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—VEGFA—atherosclerosis	4.02e-06	3.44e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL6—atherosclerosis	4.02e-06	3.44e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—STAT3—atherosclerosis	3.98e-06	3.41e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—IL6—atherosclerosis	3.97e-06	3.4e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—AKT1—atherosclerosis	3.97e-06	3.4e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ABCA1—atherosclerosis	3.93e-06	3.37e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MAPK3—atherosclerosis	3.8e-06	3.26e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CG—atherosclerosis	3.79e-06	3.25e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ALB—atherosclerosis	3.77e-06	3.23e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—AKT1—atherosclerosis	3.71e-06	3.17e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TGFB1—atherosclerosis	3.69e-06	3.16e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—AKT1—atherosclerosis	3.66e-06	3.14e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PPARG—atherosclerosis	3.66e-06	3.13e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—NOS3—atherosclerosis	3.61e-06	3.09e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—INS—atherosclerosis	3.59e-06	3.07e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HMOX1—atherosclerosis	3.37e-06	2.89e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTGS2—atherosclerosis	3.3e-06	2.83e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ALB—atherosclerosis	3.29e-06	2.82e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—APOB—atherosclerosis	3.23e-06	2.77e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—NOS3—atherosclerosis	3.15e-06	2.69e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTM1—atherosclerosis	3.14e-06	2.69e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—LPL—atherosclerosis	3.09e-06	2.64e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GPX1—atherosclerosis	3.01e-06	2.58e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CD36—atherosclerosis	2.93e-06	2.51e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—AKT1—atherosclerosis	2.89e-06	2.47e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTGS2—atherosclerosis	2.88e-06	2.46e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL6—atherosclerosis	2.78e-06	2.38e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—MTHFR—atherosclerosis	2.78e-06	2.38e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PPARA—atherosclerosis	2.73e-06	2.34e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—AKT1—atherosclerosis	2.67e-06	2.29e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—AGT—atherosclerosis	2.64e-06	2.26e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—APOE—atherosclerosis	2.59e-06	2.22e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AKT1—atherosclerosis	2.56e-06	2.2e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CAV1—atherosclerosis	2.56e-06	2.2e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—APOA1—atherosclerosis	2.56e-06	2.19e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CG—atherosclerosis	2.33e-06	2e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PPARG—atherosclerosis	2.25e-06	1.93e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—INS—atherosclerosis	2.21e-06	1.89e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ALB—atherosclerosis	2.03e-06	1.74e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NOS3—atherosclerosis	1.94e-06	1.66e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTGS2—atherosclerosis	1.77e-06	1.52e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—AKT1—atherosclerosis	1.66e-06	1.42e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—AKT1—atherosclerosis	1.45e-06	1.24e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—AKT1—atherosclerosis	8.91e-07	7.63e-06	CbGpPWpGaD
